Habot-Wilner Z, et al. - Authors estimated the data to analyze the efficacy and safety of suprachoroidal space (SCS) (region between the sclera and the choroid) use as a potential approach to target pharmacotherapies to the posterior segment through a minimally invasive injection procedure. They observed an enhancement in anatomic and visual consequences in noninfectious uveitis cases, with the potential to mitigate the known risks of cataract and increased intraocular pressure (IOP) associated with the use of intraocular corticosteroids when triamcinolone acetonide (TA) was given through suprachoroidal injection. They also noticed it as a promising treatment modality in the early stages of investigation for other possible applications, like an injection of antiglaucoma agents into the anterior SCS for long-lasting control of elevated IOP. They also found it as a useful mode of delivery for gene- or cell-based medicines for retinal ailments.